Market research
ZOM Zomedica Pharmaceuticals Corp
NYSE MKT USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 95M
- P/E ratio
- Not available
- Analyst target
- 0.25
- Dividend yield
- Not available
- Beta
- 1.16
Profile
Company facts
- Exchange
- NYSE MKT
- Currency
- USD
- Sector
- Healthcare
- Industry
- Medical Devices
- ISIN
- CA98980M1095
- Market cap
- 95M
- P/E ratio
- Not available
- Analyst target
- 0.25
- Dividend yield
- Not available
- Beta
- 1.16
About
About Zomedica Pharmaceuticals Corp
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system. It also provides therapeutic products, including PulseVet electrohydraulic shockwave therapy platform; and Assisi Loop line of products, including the Assisi Loop, Assisi Loop Lounge, and DentaLoop devices that treat pain and inflammation through delivery of targeted pulsed electromagnetic field focused energy. The company has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for the development of a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. is headquartered in Ann Arbor, Michigan.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ZOM discussion.
5 years, 4 months ago
Zomedica Corp is currently in a long term downtrend where the price is trading 20.0% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Zomedica Corp's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 100.6% to $17K since the same quarter in the previous year.
Finally, its free cash flow grew by 813.9% to $14M since the same quarter in the previous year.
Based on the above factors, Zomedica Corp gets an overall score of 3/5.